רילרט 20 מג
pfizer pfe pharmaceuticals israel ltd - eletriptan hydrobromide - טבליות מצופות פילם - eletriptan hydrobromide 24.242 mg - eletriptan
רילרט 40 מג
pfizer pfe pharmaceuticals israel ltd - eletriptan hydrobromide - טבליות מצופות פילם - eletriptan hydrobromide 48.485 mg - eletriptan
רילרט 80 מג
pfizer pfe pharmaceuticals israel ltd - eletriptan hydrobromide - טבליות מצופות פילם - eletriptan hydrobromide 96.97 mg - eletriptan
מרבוסיוה וטרינרי
m.p.vet ltd - marbofloxacin - תמיסה להזרקה - marbofloxacin 100 mg / 1 ml
אריסטוס 10 וטרינרי
romat ltd - marbofloxacin - תמיסה להזרקה - marbofloxacin 100 mg / 1 ml
צפקטאן 25 מגמל וטרינרי
romat ltd - cefquinome as sulfate - תרחיף להזרקה - cefquinome as sulfate 25 mg / 1 ml
דיפלוקאן 200 מ"ג/5 מ"ל
pfizer pharmaceuticals israel ltd - fluconazole 200 mg / 5 ml - powder for suspension - fluconazole - cryptoccosis including cryptoccocal meningitis, systemic candidiasis including candidemia, mucosal candidiasis, vaginal candidiasis, dermatomycosis all as specified in leaflet.
דיפלוקאן 50 מג5 מל
pfizer pfe pharmaceuticals israel ltd - fluconazole - אבקה להכנת תרחיף - fluconazole 50 mg / 5 ml - fluconazole - fluconazole - cryptoccosis including cryptoccocal meningitis, systemic candidiasis including candidemia, mucosal candidiasis, vaginal candidiasis, dermatomycosis all as specified in leaflet.
ויפנד 50 מג טבליות מצופות
pfizer pfe pharmaceuticals israel ltd - voriconazole - טבליות מצופות פילם - voriconazole 50 mg - voriconazole - voriconazole - treatment of: invasive aspergillosis, fluconazole-resistant serious invasive candida infections (including c. krusei) serious fungal infections caused by scedosporium spp. and fusarium spp. vfend should be administered primarily to immunocompromised patients with progressive possibly life-threatening infections. treatment of candidemia in non neutropenic patients.
ויפנד 50 מג טבליות מצופות
pfizer pfe pharmaceuticals israel ltd - voriconazole - טבליות מצופות פילם - voriconazole 50 mg - voriconazole - voriconazole - treatment of: invasive aspergillosis, fluconazole-resistant serious invasive candida infections (including c. krusei) serious fungal infections caused by scedosporium spp. and fusarium spp. vfend should be administered primarily to immunocompromised patients with progressive possibly life-threatening infections. treatment of candidemia in non neutropenic patients.